Ibogaine is not a routine or low-risk intervention. Reports of serious adverse events have made cardiac screening a central concern: ibogaine can affect cardiac electrical conduction, including QT interval prolongation, which may increase the risk of dangerous arrhythmias in susceptible people. The U.S. National Institute on Drug Abuse notes that ibogaine has been associated with potentially fatal heart complications and is not approved for medical use in the United States; its overview of psychedelic and dissociative drugs provides useful regulatory context.
Risk is not limited to a single dose window. Ibogaine is metabolized to noribogaine, an active metabolite that can persist longer and may contribute to an extended period of pharmacologic effect. A careful discussion of how ibogaine works should therefore distinguish short-term subjective experience from ongoing metabolism, monitoring needs, and uncertainty about individual response.
Neurological concerns, dehydration, electrolyte disturbance, liver function, existing heart disease, and recent substance use can complicate an already uncertain risk profile. Interaction risk may also involve medicines that affect heart rhythm, seizure threshold, serotonin signaling, or drug metabolism. Do not stop, taper, or combine prescribed medication based on a program’s general instructions alone; a medication review by an appropriately qualified clinician is the safer starting point.
Practical point: A treatment setting’s statement that screening occurs is not enough by itself. Ask what is reviewed, who reviews it, what findings can lead to deferral, and how results are documented.
